A Phase 1, Open-Label, 10 Day Safety Study

Inclusion Criteria: * Healthy males and females ≥ 18 and ≤ 65 years of age with no clinically significant abnormalities identified by a detailed medical history * Female subjects must be nonpregnant, nonlactating, and either postmenopausal for at least 2 years, surgically sterile for at least 90 days, abstinent, or agree to use contraception from 1 week prior to Day -1 until 30 days after leaving the study center. * Male subjects must be surgically sterile, abstinent, or agree to use contraception from Day -1 until 30 days after leaving the study center * BMI ≥ 18.0 kg/m2 and ≤ 35.0 kg/m2 Exclusion Criteria: * Hypersensitivity to oxazolidinones or any component in the formulation * History or current significant ophthalmologic or neurologic condition that would adversely affect the clinical assessments or confound the interpretation of the data (e.g., dense cataracts, macular degeneration, retinitis pigmentosa) * Positive hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antibody test result * Known genetic condition related to mitochondrial disease or dysfunction